AD
Anagha Damre
Abbott Healthcare Pvt. Ltd., Piramal Life Sciences Limited, Bombay College of Pharmacy, Bharati Vidyapeeth
0000-0002-5845-3163
Employment
-
Abbott Healthcare Pvt. Ltd. Director-DMPK2016 - Present
-
Piramal Life Sciences Limited Senior Group Leader & Head2003 - 2014
Education
-
Bombay College of Pharmacy Ph.D. (Tech.)1999 - 2002
-
Bombay College of Pharmacy M. Pharm.1997 - 1999
-
Bharati Vidyapeeth B. Pharm.1993 - 1997
Projects & Funding
Projects & funding information is unavailable.
Publications (44)
- Beyond traditional toxicology: The transformative power of PBTK modeling Save
- Factors Affecting Pharmacokinetics of Sunitinib and Its Metabolite, SU12662: A Systematic Review of Population Pharmacokinetic Studies Save
- Application of Physiologically Based Biopharmaceutics Modeling (PBBM) to Establish Clinically Relevant Dissolution Specifications for a Prolonged Release Tablet Formulation of Verapamil, a BCS Class I Drug Save
- Comparison of the Catalytic Competence of Different Animal Hepatic Microsomal Fractions Prepared by Calcium Aggregation and Differential Centrifugation Methods Save
- Comparison of the Catalytic Competence of Different Animal Hepatic Microsomal Fractions Prepared by Calcium Aggregation and Differential Centrifugation Methods Save
- Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b] thiazoles as dual EGFR and IGF1R inhibitors Save
- Population pharmacokinetic analysis to identify the possibility of interaction between anti-cancer agents. Save
- P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Save
- P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Save
- P7435, a Novel, Selective, and Potent DGAT1 Inhibitor as a New Therapeutic Option for Hyperlipidemia and Obesity Save